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ABSTRACT 
Objective: Low-dose， long-term use of 14-membered macrolides is effective for treatment of patients 
with chronic airway inflammation such as diffuse panbronchiolitis or chronic rhinosinusitis. However， 
long-term use of macrolides can promote the growth of drug-resistant bacteria， and the development of 
anti-inflammatory macrolides that lack antibiotic effects is desirable. Previously， we developed EM900， a 
novel12-membered erythromycin A derivative， which has potent anti-inflammatory and immunomod-
ulatory activities and lacks any antibacterial activity. We examined the anti-inflammatory effects of 
EM900 on mucus secretion from airway epithelial cels. 
Methods: To examine the in vivo effects ofEM900 on airway inflammation， we indllced hypertrophic and 
metaplastic changes of goblet cells in rat nasal epithelillm via intranasal instillation of lipopolysacchar-
ides. ln vitro effects of EM900 on airway epithelial cells were examined llsing clltlred hllman airway 
epithelial (NCI-H292) cells. MllCllS secretion was evalllated via enzyme-linked immllnosorbent assays 
with an anti-MUC5AC monoclonal antibody. 
Results: Oral administration of EM900 or clarithromycin (仁AM)significantly inhibited LPS-indllced 
mllclls production from rat nasal epithelium. EM900， CAM， or erythromycin significantly inhibited 
MUC5AC secretion indllced by tllmor necrosis factor-αfrom NCI-H292 cels. MUC5AC mRNA expression 
was also significantly lower in EM900-treated cells. 
Conclusion: These reslllts indicated that a novel non-antibiotic macrolide， EM900 exerted direct 
inhibitory effects on mllCllS secretion from airway epithelial cells， and that it may have the potential to 
become a new anti-inflammatory drllg for the treatment of chronic rhinosinllsitis. 。2015Elsevier Ireland Ltd. AII rights reserved. 
1. Introduction 
Low-dose， long-te1'm use of a 14-01' 15-membe1'ed macrolide 
such as cla1'ithl・omycin(CAM)， e1'yth1'omycin (EM)， or azithromycin 
(AZM) is a ve1'y effective t1'eatment fo1' patients with a chronic 
ai1'way disease such as diffuse panb1'onchiolitis [1]， ch1'onic 
b1'onchitis [2，3]， cystic fibrosis [4]， or ch1'onic 1'hinosinusitis 
(CRS) [5，6]. These l1seful clinical effects may depend on the anti-
inflammatory activity of macrolides rather than the antibacterial 
activity. The anti-inflammatOlY activity includes the iml1luno-
mod111ato1'Y effect on inflal1lmato1'Y cells， the modulation of 
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cytokine p1'oduction f1'om epithelial cells， and the inhibition of 
bacterial functions and biofilm formation. 
Ml1cUS hype1'sec1'etion is an impo1'tant featl11'e of ai1'way 
inflammation， and macrolide the1'apy res111ts in a significant 
1'eduction of the amount of sec1'eted ml1cl1s; spl1tl1m and 
1'hinor1'hea. In p1'evious studies， we demonst1'ated that macrolides 
inhibit hype1'sec1'etion of ml1cus in ai1'ways [7，8]. Int1'anasal 
instillation of lipopolysaccha1'ides (LPS) cal1ses inflammation of 
1'at nasal epithelil1m， and oral administ1'ation of CAM， EM， 01' 
AZM significantly inhibits the LPS-induced hype1't1'ophic and 
metaplastic changes of goblet cells in this 1'at model of ai1'way 
inflammation. CAM， EM， 01' AZM also exerts di1'ect inhibito1'Y 
effects on mucus secretion from cultured ai1'way epithelial (NCI-
H292) cells 01' human nasal epithelial cel1s. These 1'esults indicate 
that low-dose， long-te1'11l macrolide the1'apy can be useful fo1' the 
t1'eatment of hype1'sec1'eto1'Y conditions associated with chronic 
ai1'way inflammation. 
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However， long-term use of macrolides can promote the growth 
of drug-resistant bacteria， and non-antibiotic macrolide de1'iva-
tives with anti-inflammatOlY activities are desirable. Recently， 
Sunazuka and coworkers developed a novel 12-membe1'ed 
erythromycin A (EMA) derivative， (8R，9S)-8，9-dihydro-6，9-
epoxy-8，9-anhydropseudoerythromycin A (EM900) that has 
potent anti-inflammatory and immunomodulatory activities， but 
apparently lacks antibacterial activity [9，10]. In that study， the 
anti-inflammatolY activities of EMA de1'ivatives were evaluated by 
the THP-1 assay system， which examined the promotion of the 
differentiation of monocytes to macrophages. 
Here， we examined the anti-inflammatory effects of EM900 on 
mucus sec1'etion from airway epithelial cells; specifically， we 
evaluated (1) the in vivo effects of EM900 on LPS-induced mllCllS 
production in rat nasal epithelillm and (2) the in vitro effects of 
EM900 on tllmo1' necrosis factor-α(TNF-α)-induced MUC5AC 
secretion and MUC5AC mRNA expression in cultured human 
airway epithelial (NCI-H292) cells. 
2. MateriaIs and methods 
2.1. Mucus hypersecretion in rat nasal epithelium 
All expe1'iments we1'e approved by the Committee fo1' the 
Care and Use of Laborato1'Y Animals of Shiga University of 
Medical Science. LPS instillation was performed with rats as 
described previously [11]. Male Fische1' 344 rats (6 weeks old) 
were anesthetized with ether， and 0.1 mL saline containing 
0.1 mg LPS from Escherichia coli 0111: B4 (Sigma) 01' 0.1 mL 
saline control was intranasally instilled once daily for three 
consecutive days. 
EM900 was a gi仕fromT. Sunazuka (Kitasato Institute for Life 
Sciences and Gradllate School of Infection Control Sciences， 
IくitasatoUniversity， Tokyo， Japan). EM900 (1-10 mg/kg) 01' CAM 
(10 mg/kg， Taisho Phannaceutical， Tokyo) in 0.5% ca1'boxymethyl 
cellulose sodium salt was administered o1'ally exactly 1 h before 
the int1'anasal instillation of LPS on each of the th1'ee instillation 
days. Each rat was sacrificed 24 h afte1' its last int1'anasal 
instillation; the nasal cavity was then transve1'sely sectioned at 
the level ofthe incisive papilla. Paraffin sections were stained with 
alcian blue-periodic acid-Schiff(AB-PAS) or hematoxylin and eosin 
(H-E). 
2.2. Morphometry 
The amount of AB-PAS-stained mucosubstance in the su1'face 
epithelium was determined with an image analyzer (Image-P1'o 
Plus， Medical Cybernetics， Maryland) as desc1'ibed previously 
[11]. The area of nasal epithelium was outlined， and the image 
analyzer determined the area of AB-PAS-stained mucosubstances 
within this 1'efe1'ence area. The percent area of stored mllcosub-
stance per surface a1'ea was calculated over 2 mm (1mm each side 
of nasal septum) of the basal lamina at the cente1' of the septal 
ca1'tilage. 
2.3. Cell cultures 
A human mucoepide1'moid ca1'cinoma cell line， NCトH292，was 
grown on plastic dishes in RPMI 1640 medium containing 10% fetal 
bovine serum， penicillin streptomycin (50 U/mL-50μg/mL)， and 
HEPES (25 mM). EM900， CAM， or EM was dissolved in N，N-
dimethylfo1'mamide at a concentration of 10一1M， and each of 
these stock Sollltions was sto1'ed at 40C until use; each stock 
solution was diluted with the approp1'iate medium to 1'esult in a 
final concent1'ation within the range between 10-4 and 10-6 M in 
each expe1'iment. When the NCI-H292 cells become confluent， 
TNF-α， and EM900 01' CAM was added to the cultu1'e medium for 
20 h， then the culture medillm was collected and total RNA was 
extracted from each culture. 
2.4. Enzyme-linked immunosorbent assαY (ELISA) 
Each subsample of culture medium and serial dilution 
of “standard" purified human nasal mucin [12] we1'e incubated 
in one well of a 96-well plate at 40 oC until dry. Wells we1'e then 
incllbated with 2% bovine serum albumin fo1' 1 h， and then 
with 50μL of mouse monoclonal MUC5AC antibody (1: 1 00， 
Thermo Scientific， Massachusetts) for 1 h.Wells we1'e then 
incubated with 100μL of horseradish peroxidase-goat anti-
mouse IgG conjugate (1 :10，000) fo1' 1 h.Color reaction was 
developed using 3，3'，5，5'-tetramethylbenzidine peroxidase solu-
tion. Absorbance was read at 450 nm. Data were expressed as the 
percent above the control vehicle (RPMト1640)as desc1'ibed 
p1'eviously [7，8]. 
2.5. Reverse transcription-polymerase chain reαction (RT-P仁)
Total RNA was extracted from cultu1'ed cells， reve1'se tran-
scribed， then the cDNA was amplified by PCR using the Superscript 
preamplification system kit (Gibco， Grand Island， NY). The 
MUC5AC cDNA was amplified using the sense primer 5'-CACCAA 
ATA仁GCCAACAAGAC-3'and the antisense p1'ime1' 5'-CAGGGC-
CACGCAGCCAGAGAA-3'. The GAPDH cDNA was amplified using 
the sense primer 5'-CCACCCATGGCAAATTCCATGGCA-3' and the 
antisense p1'imer 5'-TCT AGACGGCAGGTCAGGTCCACC -3'. These 
steps we1'e described p1'eviollsly [7]. 
2.6. Stαtistics 
All data are expressed as mean土standarderror of the mean 
(SEM). Diffe1'ences between va1'iables were assessed via the Mann-
Whitney U test. P1'obability values of p < 0.05 were considered 
significant. 
3. Results 
3.1. In vivo ~庁ects ofmαcrolides on LPS-induced mucus production 
Intranasal instillation of LPS induced hype1'trophic and meta-
plastic changes of goblet cells in 1'at nasal septal epithelium within 
24 h afte1' the last instillation (Fig. 1). Only a few goblet cells were 
obse1'ved in untreated 01' saline-instilled control rats. Oral 
administ1'ation of EM900 (1-10 mg/kg) 01' CAM (10 mg/kg) 
inhibited LPS-induced hype1'trophic changes of goblet cells， and 
quari.titative measurement ofthe a1'ea of epithelial mucosubstance 
1'evealed a significant inhibition of intraepithelial mucus produc-
tion in EM900-01' CAM-t1'eated rats (Fig. 2). 
The number of in日lt1'atingneutrophils in nasal septal mucosa 
was signi白cantlyhigher in LPS-treated rats than in saline-t1'eated 
rats. Oral administration of EM900 or CAM slightly inhibited 
LPS-induced neutrophil infiltration， although these changes are 
statistically insigni白cant (Fig. 3). 
3.2. In vitro effects of macrolides on TNF-α-induced MUC5AC 
secretlOη 
TNF-α(20 ng/ml) stimlllated the secretion of MUC5AC mucin 
from cultured NCトH292cells. At concentrations from 10-4 to 
10-6 M， EM900 significantly inhibited TNF-α-induced MUC5AC 
secretion in a dose-dependent manner. CAM and EM showed 
inhibitory effects on TNF-α-induced MUC5AC secretion similar to 
those of EM900 (Fig. 4). 
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Fig. 2. Effects of EM900 (1-10 mgjkg) or CAM (10 mgjkg) on LPS-induced mucus 
production in rat nasal epithelium (n = 6). LPS instillations resulted in a significant 
incr回目inintraepithelial mucosubstance within 24 h after three consecutive days 
of intranasal instillations. Oral administration of EM900 or CAM significantly 
inhibited LPS-induced Il1UCUS production. Oata are shown as mean士SEM.
"p < 0.01， 'p < 0.05. i.n.， intranasal; p.o.， per os. 
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Fig. 3. Effects of EM900 (1-10 mgjkg) or CAM (10 mgjkg) on neutrophil infiltration 
in rat nasal epithelium. The number of infiltrating neutrophils in nasal septal 
mucosa was significantly higher in LPS-treated rats than in saline-treated rats. Oral 
administration of EM900 or CAM slightly inhibited LPS-induced neutrophil 
infiltration， although these changes are statistically insignificant. Oata are shown 
as mean土SEM.1 = 6， "p < 0.01. i.n.， intranasal; p.o.， per os 
Fig. 1. Light micrographs illustrating the nasal septal epithelium of rats. 
Bar = 30μm. (A) Saline-instilled control. (B) LPS-instilled rats (LPS rats). (C) 
EM900 (1 mgjkg)-treated， LPS-instilled rats. (0) EM900 (10 mgjkg)ーtreated，LPS-
instilled rats. (E) CAM (10 mgjkg)-treated， LPS-instilled rats. Hypertrophic and 
l1etaplastic changes of goblet cells were indl1ced by LPS instillation. Oral 
administration of EM900 or CAM inhibited hypertrophic ancl metaplastic 
changes of goblet cels. 
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Fig. 4. Effects of CAM， EM， or EM900 on TNF-α(20 ngjmL)ーindl1cedMUC5AC 
secretion from NCトH292cells (η= 8). At concentrations from 10-4 to 10-6 M， 
EM900 significantly inhibited TNF-αーindl1cedMUC5AC secretion in a dose-
dependent l1anner. CAM and EM showed inhibitory effects on TNF-αーindl1ced
MUC5AC secretion similar to those of EM900. Oata are expressed as the percent 
above the control vehicle (RPMト1640)，and are shown as mean土SEM."pく0.01.
Changes of MUC5AC gene expression were evaluated by RT-
PCR; EM900 (10-4 M) significantly inhibited TNF-α-induced 
MUC5AC mRNA expression in cultured NCトH292cells (Fig. 5). 
Low-dose， long-term use of 14-membered macrolides， EM or 
CAM [macrolide therapy]， has been widely used for the treatment 
ofpatients with CRS injapan [13]. Macrolide therapy is effective for 
hypersecretory conditions and for neutrophilic chronic inflamma-
tion of nasal cavity and paranasal sinuses. However， long-term use 
of macrolides can promote the growth of drug-resistant bacteria. A 
number of international and national surveillance studies have 
documented high levels ofmacrolide resistance in respiratory tract 
infection [14，15]， and more than 70% of Streptococcus pneumoniae 
are resistant to EM in japan [16]. Therefore， macrolide derivatives 
4. Discussion 
1'espi1'ato1'Y tissues such as nasal mucosa and lung [18，19]. In the 
p1'esent study， o1'al administ1'ation of 1-10 mgjkg of EM900 01' 
10 mgjkg of CAM significantly inhibited LPS-induced int1'aepithe-
lial mucus p1'oduction. These doses a1'e simila1' to the clinical CAM 
dose， and a1'e compa1'able with tissue concent1'ations of 10-4 to 
10-5 M in 1'at ai1'ways [20]. EM900， CAM， 01' EM significantly 
inhibited TNF-α-induced MUC5AC sec1'etion from cllltured ai1'way 
epithelial cells at concent1'ations f1'om 10-4 to 10-5 M. TNF-αis one 
of the p1'oinflammato1'Y mediato1's that a1'e induced by exposu1'e to 
LPS in hllman ai1'ways. LPS stimulation enhances TNF-αjs 
production in 1'at lllng [21]. and a TNF-αantagonist inhibits 
LPS-induced mucus hype1'sec1'etion in 1'at nasal epithelium 
[22]. These 1'esults indicate that in vivo effects of EM900 01' CAM 
on LPS-induced mllCUS production a1'e caused in some pa1't by a 
di1'ect inhibito1'Y effect on mucus sec1'etion from ai1'way epithelial 
cels. 
Recently， in vitro stlldy has demonst1'ated that EM900 
supp1'esses IL-1戸ーinducedcytokines and mucin exp1'ession in 
ai1'way epithelial (A549) cells; specifically， EM900 (10-5 M) 
inhibits IL-1 s-indllced exp1'ession of IL-8， TNF-α， IL-1 s， and 
MUC5AC mRNAs [23]. A NFKB-1'egulated t1'ansc1'iptional pathway 
is 1'epo1'tedly ve1'y impo1'tant fo1' IL-1 s-indllced MUC5AC exp1'es-
sion [24]. At 10-5 M， EM900 01' EM significantly inhibited IL-1s-
indllced NFKB activation. The inhibition of NFKB activation is one 
of the impo1'tant anti-inflammatOlY activities of the 14-membe1'ed 
mac1'olides， CAM and EM; impo1'tantly， EM900 has a simila1' effect 
on ai1'way epithelial cels. 
In conclusion， we induced hype1'trophic and metaplastic 
changes of goblet cells in 1'at nasal epithelium by int1'anasal LPS 
instillation， and llsing this model of ai1'way in日ammation，we 
demonst1'ated that EM900 inhibited LPS-induced epithelial mucus 
prodllction. We also demonst1'ated that EM900 di1'ectly inhibited 
TNF-α-indllced MUC5AC sec1'etion and MUC5AC mRNA exp1'ession 
in cllltu1'ed NCI-H292 cels. These inhibito1'Y effects of EM900 we1'e 
simila1' to those of CAM 01' EM. These 1'eslllts indicate that a novel， 
non-antibiotic EMA de1'ivative， EM900， has the potential to become 
a new anti-inflammatOlY d1'lg fo1' the t1'eatment of chronic 
1'hinosinusitis. 
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Fig. 5. Effects of EM900 on TNF-α(20 ng/mL)ーinducedMUC5AC mRNA expresion 
from NCI-H292 cels (n = 6). Total RNA was isolated and analyzed for MUC5AC and 
GAPDH mRNA expression by RT-PCR. EM900 significantly inhibited TNF-αーinduced
MUC5AC mRNA expression at 10-4 M as demonstrated by the MUC5AC/GAPDH 
ratio. Data are shown as mean土5EM.'pく0.05.
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